Danish drugmaker H Lundbeck rises on Q3 results beat, annual view upgrade

H Lundbeck A/S

13/11/2024 08:29

** Shares in H Lundbeck  HLUNb.CO  rise 4.2% after the
Danish drugmaker posted its Q3 print above market expectations,
raised lower end of its full-year guidance 
    ** "Third quarter results were ahead of expectations on the
topline, led by strategic products, which also led to a
significant adjusted EBITDA beat, which was positive," J.P.
Morgan analysts say in a note
    ** Co said in a statement it has raised its full-year
guidance, now forecasting 12%-14% revenue growth at CER, up from
11%-14%, and 17%-20% adjusted EBITDA growth, previously 15%-20%
    ** JPM notes the upward adjustment of the company's
full-year guidance as positive, expecting a slight share price
outperformance today
    ** Including session's rise the stock has gained 29.62 % YTD
    
    

 (Reporting by Jesus Calero)
 ((Jesus.calero@thomsonreuters.com))